Andrew Hill,
Professor and ARC Future Fellow,
The University of Melbourne
Andrew Hill is Professor of Biochemistry and Molecular Biology and an Associate Director of the Bio21 Institute at the University of Melbourne. He has studied neurodegenerative diseases for the last 20 years, first undertaking his PhD at Imperial College, London, where he developed a diagnostic and classification system for human prion diseases. In 2000 he moved to the University of Melbourne where established his lab which now studies the molecular and cellular biology of Alzheimer’s, Parkinson’s and prion diseases. Over the last 7 years he has developed an interest in the study of extracellular vesicles and their role in neurodegeneration. Recently, this has led to new studies employing the use of next generation deep sequencing to analyse the RNA content of exosomes in a number of experimental and clinically relevant settings. His work has been published in some of the top scientific journals including Nature, Science, Cell and PNAS and he has been the recipient of several awards and prizes including the 2005 ASBMB Edman Award, a Young Tall Poppy Award in 2006, the ASBMB Merck Research Excellence Medal for 2010. He has published over 120 peer reviewed publications, edited two books, and is on the editorial board of 3 journals. He is currently an Australian Research Council Future Fellow, an honorary National Health and Medical Research Council Senior Research Fellow, and an elected member of the Executive of the International Society of Extracellular Vesicles.
Deep sequencing of RNA from Exosomes: Applications for Biomarker Discovery
Tuesday, 25 February 2014 at 15:30
Add to Calendar ▼2014-02-25 15:30:002014-02-25 16:30:00Europe/LondonDeep sequencing of RNA from Exosomes: Applications for Biomarker DiscoveryNext Generation Sequencing: Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Exosomes are small vesicles released by cells into the extracellular space. They can be isolated from many biological fluids, including blood fractions, cerebrospinal fluid, and urine. Exosomes contain proteins, lipids and genetic material in the form of RNA, often reflecting the state of the cell of origin in the makeup of these components. In diseases such as cancer, the expression profile of certain miRNA’s is altered in exosomes, providing their potential use as sources of biomarkers. We study neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and prion diseases. These are all diseases of our ageing population, are associated with proteins that misfold and deposit in the brain and are difficult to easily diagnose in the living patient. Work from our lab and other have shown that the proteins responsible for these diseases are associated with exosomes, suggesting these vesicles may play a role in the disease process. We have used next generation deep sequencing to analyse the RNA content of exosomes from both cell culture models and human clinical samples. This presentation will discuss our findings relating to the use of deep sequencing for analysing the genetic content of exosomes, the sample preparation required for such work, and highlight how these technologies can be utilised in biomarker discovery using exosomes as a target.
Add to Calendar ▼2014-02-24 00:00:002014-02-25 00:00:00Europe/LondonNext Generation Sequencing: Research to ClinicNext Generation Sequencing: Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2014-02-25 15:30:002014-02-25 16:30:00Europe/LondonDeep sequencing of RNA from Exosomes: Applications for Biomarker DiscoveryNext Generation Sequencing: Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
